

IRONWOOD PHARMACEUTICALS INC  
Form 8-K  
March 08, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report Pursuant to**  
**Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported):

**March 8, 2019**

**IRONWOOD PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34620**  
(Commission File Number)

**04-3404176**  
(I.R.S. Employer  
Identification Number)

**301 Binney Street**  
**Cambridge, Massachusetts**  
(Address of principal  
executive offices)

**02142**  
(Zip code)

**(617) 621-7722**

Edgar Filing: IRONWOOD PHARMACEUTICALS INC - Form 8-K

(Registrant's telephone  
number,

including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events**

In connection with the planned separation of Ironwood Pharmaceuticals, Inc. ( Ironwood ) and Cycleron Therapeutics, Inc. ( Cycleron ) into two independent, publicly traded companies, the Ironwood board of directors has set March 19, 2019 as the record date for the dividend of shares of common stock of Cycleron to be distributed to Ironwood stockholders in order to effect the separation. Each Ironwood stockholder of record as of the close of business on March 19, 2019 will receive, on the distribution date, one share of Cycleron common stock for every 10 shares of Ironwood common stock held. The share dividend is expected to be distributed to Ironwood stockholders on April 1, 2019. Following the separation, such Ironwood stockholders will also receive cash in lieu of any fractional shares of Cycleron common stock that those holders would have received after application of the above ratio.

Distribution of the Cycleron share dividend is subject to the Securities and Exchange Commission (the SEC ) having declared effective Cycleron s Registration Statement on Form 10 (the Form 10 ) and completion of the listing process for Cycleron to trade on the Nasdaq Global Market. The completion of the separation is also subject to other conditions described in the Form 10, including those conditions set forth in the Separation Agreement to be entered into between Ironwood and Cycleron, the form of which is filed as an exhibit to the Form 10.

No action is required by Ironwood stockholders in order to receive the shares of Cycleron common stock in the dividend distribution. Following the effectiveness of the Form 10, Ironwood plans to provide further information regarding the expected commencement of the when-issued trading for Cycleron common stock and ex-distribution trading for Ironwood common stock. A description of these expected trading markets is included in the Form 10. After the separation, Cycleron common stock is expected to trade on the Nasdaq Global Market under the stock ticker symbol CYCN and Ironwood will continue to trade on Nasdaq Global Market under the stock ticker symbol IRWD.

*This Current Report on Form 8-K contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the completion, structure, timing and terms of the planned separation, the distribution and markets for Ironwood and Cycleron stock. Each forward-looking statement is subject to risks and uncertainties that could cause actual events to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to the possibility that Ironwood may not complete the separation on the terms or timing currently contemplated, if at all; and the risks listed under the heading Risk Factors and elsewhere in Ironwood s Annual Report on Form 10-K filed with the SEC on February 25, 2019, and in Ironwood s subsequent SEC filings, including SEC filings related to the planned separation, and in the Form 10. These forward-looking statements (except as otherwise noted) speak only as of the date of this Current Report on Form 8-K, and Ironwood undertakes no obligation to update these forward-looking statements.*

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Ironwood Pharmaceuticals, Inc.**

Dated: March 8, 2019

By:	/s/ Gina Consylman	
Name:		Gina Consylman
Title:		Senior Vice President, Chief Financial Officer